NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Aridis Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 01:31 PM Eastern

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.05
Volume
592 shs
Average Volume
24,390 shs
Market Capitalization
$5.33 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aridis Pharmaceuticals is a biopharmaceutical company focused on developing antibody-based treatments for infectious diseases, particularly serious bacterial and respiratory infections. Its work has included therapies intended to complement antibiotics by targeting toxins or other components of disease-causing bacteria.

The company’s research programs have included AR-301, a monoclonal antibody targeting Staphylococcus aureus alpha toxin, investigated as a potential treatment for severe pneumonia. Aridis has also developed other antibody candidates for infectious diseases using its antibody-discovery technologies.

Founded in 2003 and based in San Jose, California, Aridis was founded by Vu Truong, who has served as the company’s chief executive officer. Its development programs have been conducted primarily in the United States.

AI Generated. May Contain Errors.

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARDS Stock News Headlines

Aridis Pharmaceuticals, Inc. (ARDS) - Yahoo Finance
Aridis Provides Corporate Update
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Aridis Provides Corporate Update
See More Headlines

ARDS Stock Analysis - Frequently Asked Questions

Aridis Pharmaceuticals' stock was trading at $0.0002 at the beginning of 2026. Since then, ARDS shares have decreased by 50.0% and is now trading at $0.0001.

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company had revenue of $520 thousand for the quarter.

Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Salesforce (CRM), Abeona Therapeutics (ABEO), ADMA Biologics (ADMA), Ardelyx (ARDX), Axcella Health (AXLA) and Aytu BioPharma (AYTU).

Company Calendar

Today
11/19/2026
Next Earnings (Estimated)
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ARDS
CIK
1614067
Employees
30
Year Founded
2003

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
53,321,000
Free Float
50,388,000
Market Cap
$5.33 thousand
Optionable
Not Optionable
Beta
55.49

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:ARDS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners